Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Ricardo Dent"'
Autor:
John N. Booth, Lisandro D. Colantonio, Robert S. Rosenson, Monika M. Safford, Ligong Chen, Meredith L. Kilgore, Todd M. Brown, Benjamin Taylor, Ricardo Dent, Keri L. Monda, Paul Muntner, Emily B. Levitan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 10 (2018)
BackgroundContact with the healthcare system represents an opportunity for individuals who discontinue statins to re‐initiate treatment. To help identify opportunities for healthcare providers to emphasize the risk‐lowering benefits accrued throu
Externí odkaz:
https://doaj.org/article/33bb62b12a4b4076aa463cd67b294eda
Autor:
Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 10 (2017)
BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reducti
Externí odkaz:
https://doaj.org/article/7f9fd7632f2a455c94947fb72b3ea045
Autor:
Quinn S Wells, Eric Farber-Eger, Loren Lipworth, Paul Dluzniewski, Ricardo Dent, John Umeijiego, Sarah S Cohen
Publikováno v:
Clinical Epidemiology
Quinn S Wells,1,2 Eric Farber-Eger,1,2 Loren Lipworth,2,3 Paul Dluzniewski,4 Ricardo Dent,4 John Umeijiego,4 Sarah S Cohen3,5 1Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 2Van
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbc70defde3983f700fab8ff9516891d
https://www.dovepress.com/characterizing-a-clinical-trial--representative-real-world-population--peer-reviewed-fulltext-article-CLEP
https://www.dovepress.com/characterizing-a-clinical-trial--representative-real-world-population--peer-reviewed-fulltext-article-CLEP
Publikováno v:
Circulation. 142
Introduction: Real world evidence (RWE) is increasingly used for regulatory and market access decision-making. In heart failure (HF), typical structured datasets have limitations in data accuracy and identifying relevant patient characteristics. Unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d83757053f8e64bd20e87f499b6aed14
https://doi.org/10.1161/circ.142.suppl_3.13797
https://doi.org/10.1161/circ.142.suppl_3.13797
Autor:
Keri L. Monda, Jeffrey S. Riesmeyer, Ricardo Dent, Robert A. Scott, Manisha Desai, Robert LoCasale, Jesse A. Berlin, Joanne Waldstreicher, Jyothis T. George, Cherie Binns, Thomas Hucko, Debbe McCall, Jack Mardekian, Lothar Roessig, Govinda Weerakkody, Harald Siedentop, Stefan Hantel, Shun Fu Lee, Andrea J. Cook, Lin Wang, Tomas Andersson, Adrian F. Hernandez, Carolyn Arias, Denise Esserman, Frank W. Rockhold, Susan S. Ellenberg, Sharon-Lise T. Normand, Mark J. Cziraky, Matthew T. Roe, Lesley H. Curtis, Andrew Emmett, Trevor A. Lentz, Naeem D. Khan, David Martin, Patrick J. Heagerty, Myles Wolf
Publikováno v:
Therapeutic innovationregulatory science. 54(6)
In late 2018, the Food and Drug Administration (FDA) outlined a framework for evaluating the possible use of real-world evidence (RWE) to support regulatory decision-making. This framework was created to facilitate studies that would generate high-qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7942a1dd78e35dbba8a4aad90b4e0d99
https://pubmed.ncbi.nlm.nih.gov/32514736
https://pubmed.ncbi.nlm.nih.gov/32514736
Autor:
Michael E. Farkouh, Monika M. Safford, Keri L. Monda, Gabriel S. Tajeu, Matthew T. Mefford, Rikki M. Tanner, Robert S. Rosenson, Paul Muntner, Lisandro D. Colantonio, Ricardo Dent
Publikováno v:
Am J Cardiol
Guidelines recommend attempting to re-initiate statins in patients who discontinue treatment. Prior experiences while taking a statin, including side effects, may reduce a person’s willingness to re-initiate treatment. We determined the percentage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e75c36086fe6f2cce1da8afca8b45dd9
https://doi.org/10.1016/j.amjcard.2018.05.016
https://doi.org/10.1016/j.amjcard.2018.05.016
Autor:
Ricardo Dent, David R. Sullivan, Ian Bridges, G. Kees Hovingh, Armando Lira, Blai Coll, Claudia Stefanutti, Frederick J. Raal, Olivier S. Descamps, Luis Masana
Publikováno v:
Journal of clinical lipidology, 11(6), 1448-1457. Elsevier BV
Background Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in patients with heterozygous familial hypercholesterolemia (HeFH) as demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f928e3356d391483237c1f1e50f43b5
https://doi.org/10.1016/j.jacl.2017.09.003
https://doi.org/10.1016/j.jacl.2017.09.003
Autor:
Ronan O’Beirne, Keri L. Monda, Ricardo Dent, Paul Muntner, Rikki M. Tanner, Lisandro D. Colantonio, Robert S. Rosenson, Monika M. Safford, Benjamin Taylor, Melanie S. Morris
Publikováno v:
Cardiovascular Drugs and Therapy. 31:303-309
PURPOSE: Discontinuation of statin therapy represents a major challenge for effective cardiovascular disease prevention. It is unclear how often primary care physicians (PCPs) re-initiate statins and what barriers they encounter. We aimed to identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5597d1463ecf75d0279fd734b0b12988
https://doi.org/10.1007/s10557-017-6738-x
https://doi.org/10.1007/s10557-017-6738-x
Autor:
Ricardo Dent, Shia T. Kent, Lisandro D. Colantonio, Robert S. Rosenson, Keri L. Monda, Paul Muntner, Vera Bittner, Lei Huang, Angelika Manthripragada, Ligong Chen, Maria-Corina Serban, Maciej Banach
Publikováno v:
Journal of the American College of Cardiology. 69:1386-1395
Background Many patients report adverse reactions to, and may not tolerate, statin therapy. These patients may be at increased risk for coronary heart disease (CHD) events and mortality. Objectives This study evaluated the risk for recurrent myocardi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c0bedfda5cbce10b21dab0e99180fa6
https://doi.org/10.1016/j.jacc.2016.12.036
https://doi.org/10.1016/j.jacc.2016.12.036
Autor:
Rob Scott, Gerald F. Watts, Scott M. Wasserman, Ransi Somaratne, Ricardo Dent, Dick C. Chan, P. Hugh R. Barrett, Sally Burrows
Publikováno v:
Circulation. 135:338-351
Background: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations. Evolocumab is under investigation for its effects on cardiovas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a21caa18784ab2c9c4024bc07ad6a5d4
https://doi.org/10.1161/circulationaha.116.025080
https://doi.org/10.1161/circulationaha.116.025080